About the Event
Can-Fite BioPharma (NYSE: CANF) has just released results of a study that shows a CBD rich T3/C15 cannabis fraction inhibited the growth of cancerous liver cells. It is another major announcement from a company that has made a lot of news lately.
- Can-Fite has existing out-licensing deals worth up to $130 million.
- They completed a successful preclinical study for a topical ED treatment.
- Their drug candidate Namodenoson is expected to enter a pivotal Phase III study in Q4 2021.
Join our webinar to hear from Can-Fite CEO, Pnina Fishman as she shares details on all the company’s latest news and their plans for the future.